Article Sidebar

PDF (Tiếng Việt)
Published: 2022-02-22
Abstract Views: 270
Views PDF (Tiếng Việt): 251
DOI: https://doi.org/10.52852/tcncyh.v150i2.733
Issue
Vol. 150 No. 2 (2022)
Section
Các bài báo
How to Cite
Sơn, H. X., Quyết, V. B., & Trung, N. V. (2022). Identification of nucleotide variants in E6, E7 and L1 genes of human papillomavirus type 16 and 18 in cerviral cancer patients. Journal of Medical Research, 150(2), 107-115. https://doi.org/10.52852/tcncyh.v150i2.733

Identification of nucleotide variants in E6, E7 and L1 genes of human papillomavirus type 16 and 18 in cerviral cancer patients

Hoang Xuan Son, Vu Ba Quyet, Nguyen Vu Trung

Main Article Content

Abstract

Types 16 and 18 of human papillomavirus have a very high rate of causing cervical cancer. Studies show that mutations in the nucleotide sequence in the genome of types 16 and 18 can promote cervical cancer progression and other symptoms in patients. In this study, we analyzed changes in nucleotide sequences of genes E6, E7 and L1 of two HPV types 16 and 18 in patients with confirmed cervical cancer. 104 patients were screened to include 63 patients in the study of which 46 cases are HPV-16 single infection and 17 cases are HPV-18 single infection. The results of nucleotide sequence analysis of the E6, E7, L1 genes of these types showed that Type HPV 16 has 13 mutations found in the E6 gene; the highest mutation rate was T350G at 100%, the lowest is A378G at 10.9%. C578T site of the E7 gene had the highest mutation rate at 60.9% and the lowest was A739G at 13.0%. 40 mutations were identified in the L1 gene, of which the G7060A mutation had the highest rate of 80.4%. In HPV Type 18, there are 14 mutations in the E6 gene, the highest rate was G532T at 41.2%; On the E7 gene, 6 mutations were found, of which mutations C894T and C898T accounted for 47.1%. There were 24 mutations found in the L1 gene, the highest mutation appeared at position G5612T at 17.6%.

Article Details

Keywords

Cervical cancer, HPV, mutations, genes E6, E7, L1

References

1. H. zur Hausen, Papillomaviruses in the causation of human cancers - a brief historical account, Virology. 2009; 384(2): 260-265.
2. Iancu IV, Anton G, Botezatu A, Huica I, Nastase A, Socolov DG, et al. LINC01101 and LINC00277 expression levels as novel factors in HPVinduced cervical neoplasia. J Cell Mol Med. 2017; 21(12): 3787–94.
3. Zhao JW, Fang F, Guo Y, et al. HPV16 integration probably contributes to cervical oncogenesis through interrupting tumor suppressor genes and inducing chromosome instability. J Exp Clin Cancer Res. 2016; 35(1): 180.
4. Yang Y, Ren J, Zhang Q. Distribution of human papilloma virus type 16 E6/ E7 gene mutation in cervical precancer or cancer: a case control study in Guizhou Province, China. J Med Virol. 2016; 88(2): 345–50.
5. Song D, Shi Q, Hou X, Zhenghai MA. The effect of mutations in the upstream regulatory region of HPV-16 on the activity of virus early promoter. China Oncol. 2017; 27(2): 109-14.
6. Arroyo SL, Basaras M, Arrese E, et al. Human papillomavirus (HPV) genotype 18 variants in patients with clinical manifestations of HPV related infections in Bilbao, Spain. Virol J. 2012; 9: 258.
7. Xu HH, Zheng LZ, Lin AF, Dong SS, Chai ZY, Yan WH. Human papillomavirus (HPV) 18 genetic variants and cervical cancer risk in Taizhou area, China. Gene. 2018; 647: 192-197.
8. Doan Van Khuong, Nguyen Vuong (2017). Histologycal pattern and servival time after treatment forr uterine adenocarcinoma. Vietnam Journal of Oncology. 1: 150-56.
9. Lopera EA, Baena A, Florez V, Montiel J, Duque C, Ramirez T, et al. Unexpected inverse correlation between Native American ancestry and Asian Zhe et al. Cancer Cell Int (2019) 19: 65 Page 11 of 11
10. M. Cui, N. Chan, M. Liu, K. Thai, J. Malaczynska, I. Singh, D. Zhang, and F. Ye, “Clinical performance of roche Cobas 4800 HPV test,” J. Clin. Microbiol. 2014; 52(6): 2210-2211.
11. Aanchal Jain, Balasubramaniam Ganesh, Saurabh C Bobdey, Jignasa A Sathwara, and Sushma Saoba (2017), Sociological and clinical profile of cervical cancer patient visiting a tertiary care hospital in India.
12. L. T. H. Vu and H. T. T. Le, “Cervical Human Papilloma Virus Infection among the General Female Population in Vietnam: A Situation Analysis,”. 2011; 12: 561-566.
13. Lam Duc Tam, Tran Ngoc Dung, Nguyen Vu Quoc Huy (2016). Evaluate the results of treatment of cervical lesions by cryotherapy in Can Tho. Hue University, University of Medicine and Pharmacy Journal of Obstetyrics and Gynecology. 13(4): 52-57.
14. Nguyen Thi Phuong Mai, Pham Van Thuc, Pham Van Han, Nguyen Hung Cuong, Pham Thi Thanh Huyen, Hiroshi Ichimura, Ta Thanh Van (2015). Variants E6, E7 of Human papillomavirus 16 in cevical cancer patients in the North, Vietnam. Journal of Practical Medecine. 966: 423-426.
15. T. Q. Vinh, C. N. Thanh, (2010), Study on Human papiloma vius infection in women with precancerous lesions and cervical cancer, Journal of Practical Medicine, Ministry of Health. 718-719: 229-240.
16. Xiangyi Zhe, Dongdong Cao, Ying Li, Chunhe Zhang, Shaowei Fu, Renfu Shao and Zemin Pan, Genetic variations in E6, E7 and the long control region of human papillomavirus type 16 among patients with cervical lesions in Xinjiang, China (2019).
17. Wu LX, Yun LI, Mu LI, Li FX, Cui MY, Yang Y, et al. The expression and clinical significance of Sox 11 in cervical carcinogenesis. J Xi’an Jiaotong Univ MedicalSciences). 2018; 39(1): 73-7. 2013; 11(1): 19-30.